Lv31
368 积分 2026-07-29 加入
Abstract 7303: A novel anti-PD-L1/VEGF bispecific antibody (HLX37) with immune checkpoint inhibition, anti-angiogenic, and antineoplastic activities
1个月前
已关闭
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
1个月前
已完结
Supportive oncology care at home after discharge for patients with advanced cancer
23天前
已采纳
Hospital at Home in an oncology setting: Updated analysis
23天前
已采纳
Novel GPC3-targeting radiopharmaceutical therapy for hepatocellular carcinoma
23天前
已采纳
Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial
23天前
已采纳
The acceptability of hospital-at-home for persons living with cancer and their caregivers
23天前
已采纳
Automated cancer data extraction using large language models: A scalable workflow for clinical documentation processing
23天前
已采纳
Plasma-TMB (pTMB) and circulating tumor fraction (ctF) dynamics as biomarkers of benefit from the addition of atezolizumab to first-line FOLFOXIRI/bevacizumab in metastatic colorectal cancer (mCRC): A translational analysis of the AtezoTRIBE study
23天前
已采纳
Influence of pirfenidone on checkpoint inhibitor pneumonitis and antitumor efficacy in NSCLC: A multicenter study and mechanistic exploration
23天前
已采纳
First-in-human PET imaging of 68 Ga-FC516, a novel ACP3-targeted radiotracer for prostate cancer
23天前
已采纳
Correlative analysis of ctDNA in CheckMate-9X8 study of frontline treatment with mFOLFOX6, bevacizumab with or without nivolumab in metastatic colorectal cancer
23天前
已采纳
皖公网安备34019202002308
